-DOCSTART- -X- O
Background. -X- _ O
Few -X- _ O
studies -X- _ O
have -X- _ O
prospectively -X- _ O
assessed -X- _ O
viral -X- _ O
etiologies -X- _ O
of -X- _ O
acute -X- _ O
respiratory -X- _ O
infections -X- _ O
in -X- _ O
community-based -X- _ O
elderly -X- _ O
individuals. -X- _ O
We -X- _ O
assessed -X- _ O
viral -X- _ B-Outcome
respiratory -X- _ I-Outcome
pathogens -X- _ I-Outcome
in -X- _ O
individuals -X- _ B-Patient
≥65 -X- _ I-Patient
years -X- _ I-Patient
with -X- _ I-Patient
influenza-like -X- _ I-Patient
illness -X- _ I-Patient
( -X- _ I-Patient
ILI -X- _ I-Patient
) -X- _ I-Patient
. -X- _ O
Methods. -X- _ O
Multiplex -X- _ O
reverse-transcriptase -X- _ O
polymerase -X- _ O
chain -X- _ O
reaction -X- _ O
identified -X- _ O
viral -X- _ O
pathogens -X- _ O
in -X- _ O
nasal -X- _ O
/ -X- _ O
throat -X- _ O
swabs -X- _ O
from -X- _ O
556 -X- _ O
episodes -X- _ O
of -X- _ O
moderate-to-severe -X- _ O
ILI -X- _ O
, -X- _ O
defined -X- _ O
as -X- _ O
ILI -X- _ O
with -X- _ O
pneumonia -X- _ O
, -X- _ O
hospitalization -X- _ O
, -X- _ O
or -X- _ O
maximum -X- _ O
daily -X- _ O
influenza -X- _ O
symptom -X- _ O
severity -X- _ O
score -X- _ O
( -X- _ O
ISS -X- _ O
) -X- _ O
> -X- _ O
2. -X- _ O
Cases -X- _ O
were -X- _ O
selected -X- _ O
from -X- _ O
a -X- _ O
randomized -X- _ O
trial -X- _ O
of -X- _ O
an -X- _ O
adjuvanted -X- _ O
vs -X- _ O
nonadjuvanted -X- _ O
influenza -X- _ O
vaccine -X- _ O
conducted -X- _ O
in -X- _ O
elderly -X- _ O
adults -X- _ O
from -X- _ O
15 -X- _ O
countries. -X- _ O
Results. -X- _ O
Respiratory -X- _ B-Outcome
syncytial -X- _ I-Outcome
virus -X- _ I-Outcome
( -X- _ I-Outcome
RSV -X- _ I-Outcome
) -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
7.4 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
41 -X- _ I-Outcome
/ -X- _ I-Outcome
556 -X- _ I-Outcome
) -X- _ I-Outcome
moderate-to-severe -X- _ I-Outcome
ILI -X- _ I-Outcome
episodes -X- _ I-Outcome
in -X- _ I-Outcome
elderly -X- _ I-Outcome
adults. -X- _ I-Outcome
Most -X- _ I-Outcome
( -X- _ I-Outcome
39 -X- _ I-Outcome
/ -X- _ I-Outcome
41 -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
single -X- _ I-Outcome
infections. -X- _ I-Outcome
There -X- _ I-Outcome
was -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
association -X- _ I-Outcome
between -X- _ I-Outcome
country -X- _ I-Outcome
and -X- _ I-Outcome
RSV -X- _ I-Outcome
detection -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
.004 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
RSV -X- _ I-Outcome
prevalence -X- _ I-Outcome
was -X- _ I-Outcome
7.1 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
2 -X- _ I-Outcome
/ -X- _ I-Outcome
28 -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
ILI -X- _ I-Outcome
with -X- _ I-Outcome
pneumonia -X- _ I-Outcome
, -X- _ I-Outcome
12.5 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
8 -X- _ I-Outcome
/ -X- _ I-Outcome
64 -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
ILI -X- _ I-Outcome
with -X- _ I-Outcome
hospitalization -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
6.7 -X- _ I-Outcome
% -X- _ I-Outcome
( -X- _ I-Outcome
32 -X- _ I-Outcome
/ -X- _ I-Outcome
480 -X- _ I-Outcome
) -X- _ I-Outcome
in -X- _ I-Outcome
ILI -X- _ I-Outcome
with -X- _ I-Outcome
maximum -X- _ I-Outcome
ISS -X- _ I-Outcome
> -X- _ I-Outcome
2. -X- _ I-Outcome
Any -X- _ I-Outcome
virus -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
320 -X- _ I-Outcome
/ -X- _ I-Outcome
556 -X- _ I-Outcome
( -X- _ I-Outcome
57.6 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
ILI -X- _ I-Outcome
episodes -X- _ I-Outcome
: -X- _ I-Outcome
influenza -X- _ I-Outcome
A -X- _ I-Outcome
( -X- _ I-Outcome
104 -X- _ I-Outcome
/ -X- _ I-Outcome
556 -X- _ I-Outcome
, -X- _ I-Outcome
18.7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
rhinovirus -X- _ I-Outcome
/ -X- _ I-Outcome
enterovirus -X- _ I-Outcome
( -X- _ I-Outcome
82 -X- _ I-Outcome
/ -X- _ I-Outcome
556 -X- _ I-Outcome
, -X- _ I-Outcome
14.7 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
coronavirus -X- _ I-Outcome
and -X- _ I-Outcome
human -X- _ I-Outcome
metapneumovirus -X- _ I-Outcome
( -X- _ I-Outcome
each -X- _ I-Outcome
32 -X- _ I-Outcome
/ -X- _ I-Outcome
556 -X- _ I-Outcome
, -X- _ I-Outcome
5.6 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ O
Conclusions. -X- _ O
This -X- _ O
first -X- _ O
global -X- _ O
study -X- _ O
providing -X- _ O
data -X- _ O
on -X- _ O
RSV -X- _ B-Outcome
disease -X- _ I-Outcome
in -X- _ I-Outcome
≥65 -X- _ I-Outcome
year-olds -X- _ I-Outcome
confirms -X- _ I-Outcome
that -X- _ I-Outcome
RSV -X- _ I-Outcome
is -X- _ I-Outcome
an -X- _ I-Outcome
important -X- _ I-Outcome
respiratory -X- _ I-Outcome
pathogen -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
elderly. -X- _ I-Outcome
Preventative -X- _ O
measures -X- _ O
such -X- _ O
as -X- _ O
vaccination -X- _ O
could -X- _ O
decrease -X- _ O
severe -X- _ O
respiratory -X- _ O
illnesses -X- _ O
and -X- _ O
complications -X- _ O
in -X- _ O
the -X- _ O
elderly -X- _ O
. -X- _ O

